BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion

Executive Summary

• BioNxt reported pre‑clinical study results showing >40% higher bioavailability for its cladribine oral thin film (ODF) versus conventional tablets, marking a key milestone.
• The company is moving the lead cladribine ODF program for Multiple Sclerosis (MS) into human clinical planning, with manufacturing readiness and regulatory alignment underway.
• Positive pre‑clinical data also enable expansion of the platform to Myasthenia Gravis (MG), a rare autoimmune disease, broadening the addressable market and potential commercialization pathways.

Key Details

• Pre‑clinical breakthrough: Study demonstrated >40% improvement in bioavailability for cladribine ODF compared with standard oral formulations.
• Clinical transition: Focus shifting to first‑in‑human study for MS; activities include clinical trial design, CRO partnership, manufacturing scale‑up, and regulatory strategy.
• CRO collaboration: Engaged an experienced contract research organization to de‑risk timelines and ensure high‑quality execution of the upcoming human study.
• Capital‑efficient strategy: Leverages cladribine’s existing FDA/EMA approval (Mavenclad®) to streamline safety/efficacy requirements, concentrating on bioavailability and bioequivalence.
• Platform expansion – Myasthenia Gravis: Same cladribine ODF technology repurposed for MG; anticipated accelerated, capital‑efficient pathway due to shared active ingredient and delivery format.
• Market context:
• Global MG market (7 major markets) projected ~US$6.7 billion by 2032.
• MS market generated US$32.8 billion in 2024; forecast to reach US$41.2 billion by 2034.
• Lead candidate: BNT23001 – sublingual cladribine ODF for MS, positioned as a swallow‑free alternative to Mavenclad® tablets (Merck KGaA reported >US$1 billion net sales in 2024).
• Strategic outlook: Emphasis on execution, timeline discipline, and platform‑driven value creation to support multiple high‑value autoimmune indications.

Notable Quotes

“The recent study results represent a pivotal inflection point for our cladribine oral thin film program, reinforcing confidence in the platform and accelerating our path toward human clinical evaluation.” – Hugh Rogers, Co‑Founder, CEO & Director, BioNxt Solutions Inc.